Skip to main content

Dihydropyrimidine Dehydrogenase (DPYD) Gene Variant Testing Rates and Fluoropyrimidine Use Following Pharmacogenetic Testing Among Incident Fluoropyrimidine Users: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Description

In this analysis, we describe the proportion of patients that were tested for dihydropyrimidine dehydrogenase (DPYD) gene variants among incident users of fluoropyrimidines. Additionally, we describe the rate of use of fluoropyrimidines among patients with receipt of DPYD gene variant testing or other pharmacogenetic testing.

The study period includes data from January 1, 2018 to May 31, 2025. We distributed this query to 13 Sentinel Data Partners on January 9, 2026.

Deliverables (1)
Sentinel Modular Program Report: Dihydropyrimidine Dehydrogenase (DPYD) Gene Variant Testing Rates and Fluoropyrimidine Use Following Pharmacogenetic Testing Among Incident Fluoropyrimidine Users: A Descriptive Analysis
Additional Details
FDA Center
CDER
Time Period
January 01, 2018 - May 31, 2025
Analysis Type
Descriptive
Population / Cohort
All individuals
Data Sources
Sentinel Distributed Database (SDD)